Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Gilead Sciences Inc. has divulged bridged tricyclic carbamoylpyridone prodrugs acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infection.

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Issue: Whether the U.S. Court of Appeals for the 5th Circuit erred in holding that the structure of the U.S. Preventive ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

Trump orders are undermining HIV efforts by barring funds from programs built around diversity, equity, and inclusion. A Day ...

A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

Gilead will pay $202 million to resolve claims that it paid kickbacks to healthcare providers in the form of honoraria, meals ...

Here are 10 recent healthcare industry lawsuits, settlements and legal developments that Becker's has reported since April 22: ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.